Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) Net Income towards Common Stockholders (2025)

Drugs Made In America Acquisition filings provide 1 years of Net Income towards Common Stockholders readings, the most recent being -$1.8 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders changed N/A to -$1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.0 million for FY2025, 813.29% up from the prior year.
  • Net Income towards Common Stockholders hit -$1.8 million in Q4 2025 for Drugs Made In America Acquisition, down from $1.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.6 million in Q2 2025 and bottomed at -$1.8 million in Q4 2025.